Nephron
Original Paper
Serum and Urinary Alpha-1 Acid Glycoprotein in Chronic Renal FailureVasson M.P.a · Baguet J.C.b · Arveiller M.R.c · Bargnoux P.J.d · Giroud J.P.c · Raichvarg D.aaLaboratoire de Biochimie, Faculté de Pharmacie; bService de Néphrologie, CHRU, Clermont-Ferrand; cDépartement de Pharmacologie, Hôpital Cochin, Paris; dLaboratoire de Biochimie, Centre Jean-Perrin, Clermont-Ferrand, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Accepted: November 06, 1992
Published online: December 12, 2008
Issue release date: 1993
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Abstract
The concentration and concanavalin A (ConA)-dependent microheterogeneity of serum and urinary α1-acid glycoprotein (AGP) were studied in patients with various degrees of renal impairment and compared with healthy control values. Serum concentrations of AGP were significantly higher in hemodialyzed and uremic patients than in the control subjects (1.54 ± 0.42 g/l, p < 0.05, and 1.20 ± 0.40 g/l, p < 0.05, respectively, versus 0.83 ± 0.17 g/l). There was a similar increase in serum α1-protease inhibitor and haptoglobin concentrations in the uremic patients (r = 0.87 and r = 0.70; p < 0.001). Urinary concentrations of AGP were also significantly higher in the hemodialyzed and uremic patients than in the control subjects, despite wide variability in the patients (20 ± 14 mg/24 h, p < 0.05, and 126 ± 160 mg/24 h, p < 0.05, respectively, versus 3 ± 1 mg/24 h). AGP clearance was significantly higher in the uremic patients than in the hemodialyzed patients (p < 0.01) and the control subjects (p < 0.01). The proportions of strongly ConA-reactive AGP fractions were higher in the serum of the hemodialyzed (18.6 ± 5.2%; p < 0.05) and uremic patients (18.1 ± 5.3%; p < 0.05) than in the control subjects (14.5 ± 2.5%). There was a similar difference in the urine samples (26.7 ± 8.2%, p < 0.01; 20.1 ± 6.2%, p < 0.0l, respectively, versus 10.3 ± 4.8%), with also a significant difference between the hemodialyzed and uremic patients (p < 0.05). Moreover, there was a correlation between serum and urinary levels of the strongly ConA-reactive AGP fractions in the uremic patients (r = 0.85). These results show that serum and urinary levels of biantennary AGP glycans are elevated in chronic renal failure not yet requiring hemodialysis, changes that did not seem to depend on the duration or the degree of renal failure. This reflects a chronic inflammatory state, probably due to altered cytokine secretion (principally interleukin-1, interleukin-6 and tumor necrosis factor-α).
© 1993 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Accepted: November 06, 1992
Published online: December 12, 2008
Issue release date: 1993
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 1660-8151 (Print)
eISSN: 2235-3186 (Online)
For additional information: https://www.karger.com/NEF
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
